Insmed Q2 2024 GAAP EPS $(1.94) Misses $(1.24) Estimate, Sales $90.340M Beat $87.950M Estimate
Portfolio Pulse from Benzinga Newsdesk
Insmed reported its Q2 2024 financial results with a GAAP EPS of $(1.94), missing the estimate of $(1.24). However, the company reported sales of $90.340 million, beating the estimate of $87.950 million.
August 08, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Insmed's Q2 2024 GAAP EPS of $(1.94) missed the estimate of $(1.24), but sales of $90.340 million beat the estimate of $87.950 million.
The mixed results, with a significant EPS miss but a sales beat, create a neutral short-term outlook for Insmed. Investors may react cautiously.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100